CHF Grant #02309

Dr. Angela McCleary-Wheeler, DVM, PhD
Cornell University
March 2017 - $5,000

While often treatable, canine lymphoma can rarely be cured. A continued understanding of the mechanisms causing lymphoma in dogs and identification of novel therapies are needed to improve survival. Research that has been actively explored and provided exciting breakthroughs for human lymphoma is epigenetics, or alterations in how genes are turned on and off independent of the DNA sequence. One way this occurs is through modifications of proteins that interact with DNA called histones. Modifications

to these histones can result in genes being turned on or off, leading to the development of cancer. One enzyme that modifies histones, EZH2, has been found to play a role in some human lymphomas. Given the striking similarities between human and canine lymphoma, the objective of this study is to characterize the function and role of EZH2 in canine lymphoma. The investigators will utilize an EZH2 inhibitor to study EZH2 in canine lymphoma cells, and help guide the future development of this targeted inhibitor for use as a novel therapy for canine lymphoma.